BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Celltrion Launches STOBOCLO® and OSENVELT® Biosimilars in the U.S. for Comprehensive Bone Health and Oncology Care

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and X...

July 08, 2025 | News

Koning Health Debuts in UAE with Instalalation of Region’s First No-Compression 3D Breast Imaging System

Koning Health is proud to announce the installation of the Koning Vera at the Family Health Promotion Center in Sharjah, United Arab Emirat...

June 24, 2025 | News

Clover Biopharma Begins Phase I Trial of Respiratory Combination Vaccines in Older Adults

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovat...

June 18, 2025 | News

Akesis Biologics Launches MastGut: A First-in-Class Probiotic Supplement Targeting Gut Inflammation and Colorectal Health

Akesis Biologics, a biotechnology spin-off from the National University of Singapore (NUS), has officially launched its flagship gut health product, M...

June 10, 2025 | News

Akeso’s Cadonilimab Secures NMPA Approval for First-Line Treatment of Cervical Cancer

Akeso, Inc. is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecif...

June 05, 2025 | News

Singapore Approves Astellas’ VEOZA™ (Fezolinetant) for Moderate to Severe Menopausal Vasomotor Symptoms

Astellas Singapore has announced that the Health Sciences Authority (HSA) of Singapore has approved VEOZA™ (fezolinetant) 45 mg for the treatment of ...

June 04, 2025 | News

Lunit Expands U.S. Footprint with AI-Powered Breast Cancer Screening at Over 200 Sites

Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imagi...

May 20, 2025 | News

Xuanzhu Biopharmaceutical’s Bireociclib (Xuanyuening®) Approved in China, Setting New Benchmark in HR+/HER2- Breast Cancer Treatment

National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...

May 19, 2025 | News

ASPIRE Launches Fertility Health Awareness Drive Under New President Dr Haroon Latif

The Asia Pacific Initiative on Reproduction (ASPIRE) – the peak body harnessing expertise in assisted conception throughout the region – will e...

May 12, 2025 | News

TiumBio’s Merigolix Shows Phase 2 Success in Asia for Uterine Fibroids

TiumBio (KRX: 321550.KQ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare a...

May 08, 2025 | News

AstraZeneca and Daiichi Sankyo’s ENHERTU Demonstrates Superior pCR in Early HER2+ Breast Cancer in Phase 3 DESTINY-Breast11 Trial

Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastu...